US Patent

US7671094 — Bupropion hydrobromide and therapeutic applications

Formulation · Assigned to Biovail Laboratories International SRL · Expires 2026-06-27 · 0y remaining

Vulnerability score 65/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects formulations of bupropion hydrobromide and their use in treating certain conditions.

USPTO Abstract

Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.

Drugs covered by this patent

bupropion-hydrobromide (BUPROPION HYDROBROMIDE)

Patent Metadata

Patent number: US7671094
Jurisdiction: US
Classification: Formulation
Expires: 2026-06-27
Drug substance claim: No
Drug product claim: Yes
Assignee: Biovail Laboratories International SRL
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.